Barinthus Biotherapeutics reports Q1 EPS (40c), consensus (54c)

Reports Q1 revenue $0 vs. $0.5M last year. “So far in 2024 we have continued to make strides across our programs. Notably, we received clearance from the FDA on an IND to progress VTP-1000 in a first in human clinical trial in celiac disease, as well as clearance from the Australian Ethics Committee on this trial. We expect to begin our Phase 1 trial of VTP-1000 in participants with celiac disease in the coming months. Additionally, we reported topline final data from the Phase 1b/2 trial of VTP-200 in participants with persistent high-risk human papillomavirus infections,” said Bill Enright, Chief Executive Officer of Barinthus Bio. “Looking ahead to Q2, we will present additional interim data from our VTP-300 hepatitis B trials at the European Association for the Study of the Liver Congress in June. This follows the encouraging data presented at The American Association for the Study of Liver Diseases – The Liver Meeting in November last year. We will also welcome Dr. Leon Hooftman as our new Chief Medical Officer in June and look forward to him supporting the growth of our robust pipeline and programs.”